Moreover, TRX-E-002-1 was effective against chemoresistant cancer stem cell (CD44+ MyD88+) populations in both 2D and 3D models as well as having potent cytotoxic activity against non-stem like ovarian cancer cells. Here, MYD88 is linked to ovarian carcinoma.